PTC Therapeutics
A science-led, patient-centered biopharmaceutical company focused on discovering, developing and commercializing medicine for patients with rare disease.
Launch date
Employees
Market cap
€2.3b
Enterprise valuation
€1.7b (Public information from Sep 2024)
Share price
$35.48 PTCT
South Plainfield New Jersey (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 381m | 539m | 699m | 938m | 737m | 702m | 839m |
| % growth | 24 % | 41 % | 30 % | 34 % | (21 %) | (5 %) | 20 % |
| EBITDA | (228m) | (378m) | (373m) | (103m) | (75.7m) | 89.8m | 114m |
| % EBITDA margin | (60 %) | (70 %) | (53 %) | (11 %) | (10 %) | 13 % | 14 % |
| Profit | (438m) | (524m) | (559m) | (627m) | (418m) | (355m) | (204m) |
| % profit margin | (115 %) | (97 %) | (80 %) | (67 %) | (57 %) | (51 %) | (24 %) |
| EV / revenue | 8.9x | 4.6x | 4.2x | 1.6x | 3.0x | 3.0x | 2.8x |
| EV / EBITDA | -14.9x | -6.5x | -7.9x | -14.5x | -29.5x | 23.8x | 20.4x |
| R&D budget | 478m | 541m | 651m | 667m | - | - | - |
| R&D % of revenue | 125 % | 100 % | 93 % | 71 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | Series C | |
$40.0m | Series D | ||
N/A | Series E | ||
N/A | Series E | ||
| N/A | N/A | Growth Equity VC | |
| N/A | N/A | Series F | |
| N/A | N/A | Growth Equity VC | |
| N/A | N/A | Growth Equity VC | |
$30.0m | Growth Equity VC | ||
$60.0m | Growth Equity VC | ||
| N/A | $126m Valuation: $322m | IPO | |
| N/A | $150m | Post IPO Debt | |
| N/A | $141m | Post IPO Equity | |
* | $1.0b | Post IPO Equity | |
| Total Funding | €118m | ||
Related Content
Recent News about PTC Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by PTC Therapeutics
Edit
ACQUISITION by PTC Therapeutics Jul 2018
ACQUISITION by PTC Therapeutics May 2020